Literature DB >> 10225370

The adenosine A1 receptor agonist N6-cyclopentyladenosine blocks the disruptive effect of phencyclidine on prepulse inhibition of the acoustic startle response in the rat.

T L Sills1, A Azampanah, P J Fletcher.   

Abstract

Systemic administration of the NMDA receptor antagonist phencyclidine (PCP; 4 mg/kg) produced a profound reduction in prepulse inhibition of the acoustic startle response in rats. Pre-treatment with the selective adenosine A1 receptor agonist N6-cyclopentyladenosine (CPA) blocked (0.5 mg/kg) or attenuated (0.1 and 0.2 mg/kg) the disruptive effect of PCP on prepulse inhibition. These findings suggest that adenosine may regulate the inhibitory effect of NMDA receptor blockade on prepulse inhibition, and raise the possibility that adenosine may be a potentially useful target for anti-psychotic medication. Further, 0.5 mg/kg CPA by itself was without effect on prepulse inhibition but did decrease startle amplitude, raising the possibility that adenosine, acting via A1 receptors, may be a component of the neurochemical substrate that modulates the acoustic startle response.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10225370     DOI: 10.1016/s0014-2999(99)00088-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

Review 1.  Inhibitory deficit in schizophrenia is not necessarily a GABAergic deficit.

Authors:  Diogo R Lara
Journal:  Cell Mol Neurobiol       Date:  2002-06       Impact factor: 5.046

2.  Influence of CGS 21680, a selective adenosine A(2A) agonist, on the phencyclidine-induced sensorimotor gating deficit and motor behaviour in rats.

Authors:  Jadwiga Wardas; Jolanta Konieczny; Małgorzata Pietraszek
Journal:  Psychopharmacology (Berl)       Date:  2003-04-09       Impact factor: 4.530

3.  Subchronic treatment with methamphetamine and phencyclidine differentially alters the adenosine A1 and A2A receptors in the prefrontal cortex, hippocampus, and striatum of the rat.

Authors:  Y Shirayama; K Hashimoto; T Higuchi; Y Minabe
Journal:  Neurochem Res       Date:  2001-04       Impact factor: 3.996

4.  Dipyridamole monotherapy in schizophrenia: pilot of a novel treatment approach by modulation of purinergic signaling.

Authors:  Ikwunga Wonodi; Hirekatur V Gopinath; Judy Liu; Helene Adami; L Elliot Hong; Robert Allen-Emerson; Robert P McMahon; Gunvant K Thaker
Journal:  Psychopharmacology (Berl)       Date:  2011-05-03       Impact factor: 4.530

5.  Chronic treatment with caffeine blunts the hyperlocomotor but not cognitive effects of the N-methyl-D-aspartate receptor antagonist MK-801 in mice.

Authors:  Oscar P Dall'Igna; Adriana L Da Silva; Marcelo O Dietrich; Anselmo Hoffmann; Ricardo V de Oliveira; Diogo O Souza; Diogo R Lara
Journal:  Psychopharmacology (Berl)       Date:  2003-02-13       Impact factor: 4.530

6.  Adenosine A(2A) receptors in psychopharmacology: modulators of behavior, mood and cognition.

Authors:  Hai-Ying Shen; Jiang-Fan Chen
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

Review 7.  Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders.

Authors:  Rodrigo A Cunha; Sergi Ferré; Jean-Marie Vaugeois; Jiang-Fan Chen
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

8.  Activation of adenosine(1) (A(1)) receptors suppresses head shakes induced by a serotonergic hallucinogen in rats.

Authors:  Gerard J Marek
Journal:  Neuropharmacology       Date:  2009-03-24       Impact factor: 5.250

Review 9.  Novel Therapeutic GPCRs for Psychiatric Disorders.

Authors:  Hidetoshi Komatsu
Journal:  Int J Mol Sci       Date:  2015-06-19       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.